S3 Investment Company CEO Travels to China and Mongolia for Meetings With Subsidiary Management and to Oversee Expected Closing of Redwood Capital Client Transaction
DANVILLE, Calif., Oct 26, 2010 (GlobeNewswire via COMTEX) -- S3Investment Company, Inc. /quotes/comstock/11i!sivc (SIVC 0.00, +0.00, +33.33%) today announced that Chairman and CEO Jim Bickel has traveled to China with planned stops in Mongolia and the Philippines to oversee activities of the company's Redwood subsidiaries, including the expected close of a Redwood Capital client transaction. Mr. Bickel will visit Beijing, Shanghai and Hong Kong, as well as Ulaanbaatar, Mongolia in support of Redwood Capital, Redwood Medical, the Redwood Private Equity Fund, and Redwood's newly formed Risk Investigation and Evaluation Division.
In Beijing, Shanghai and other locations in China, Mr. Bickel will work with management of Redwood Capital, which assists private Chinese companies in accessing global public markets by achieving reverse merger and financing transactions, by visiting current clients and reviewing the progress of recently signed and prospective clients. Mr. Bickel will also travel to Ulaanbaatar for meetings with a Redwood Capital client that operates in Mongolia. S3 expects to report both new client signings and the closing of a financing and public listing transaction for this Redwood Capital client in the very near future.
Mr. Bickel is currently in Ulaanbaatar and commented, "We expect to announce this major milestone for a Redwood Capital client very shortly. Additional details will be forthcoming. It is difficult to explain how exciting the prospects currently are in the Mongolia market, but as events unfold, S3 shareholders will see that the time and efforts spent on this project have been well worth it."
Mr. Bickel will also meet with the management of the Redwood Medical subsidiary in China and is expected to receive updates regarding the process of securing additional regulatory approvals for the first product it will distribute in the China market. The updates will include new information on clinical and laboratory trials, progress in the selection of hospitals for the clinical trials and the process of securing the necessary equipment and reagents.
While in Hong Kong, Mr. Bickel will attend meetings related to another potential Redwood Capital contract, the first from the Hong Kong market. Mr. Bickel will also be updated on the progress of the Redwood Private Equity Fund periodically during this trip.
To sign up to receive information by email directly from S3 Investment Company when new press releases, investor newsletters, SEC filings or other information is disclosed, please visit http://www.s3investments.com/investors/.
About S3 Investment Company, Inc.
S3 Investment Company, Inc. (http://www.s3investments.com) and its Redwood Group International subsidiary are focused on facilitating the success of several subsidiaries operating in the China market. Redwood Capital, Inc. assists private Chinese companies in accessing the North American capital markets by utilizing a network of investment banking relationships to achieve reverse merger transactions. For more information, please visit http://www.redwoodcapinc.com. Redwood Medical, Inc. assists companies seeking to import and distribute Western medical technologies and products into the China market.
Any statements contained herein related to future events are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on forward-looking statements. S3 Investment Company, Inc. undertakes no obligation to update any such statements to reflect actual events.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: S3 Investment Company, Inc. CONTACT: S3 Investment Company
Investor Relations
951-200-4107
investors@s3investments.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
In Beijing, Shanghai and other locations in China, Mr. Bickel will work with management of Redwood Capital, which assists private Chinese companies in accessing global public markets by achieving reverse merger and financing transactions, by visiting current clients and reviewing the progress of recently signed and prospective clients. Mr. Bickel will also travel to Ulaanbaatar for meetings with a Redwood Capital client that operates in Mongolia. S3 expects to report both new client signings and the closing of a financing and public listing transaction for this Redwood Capital client in the very near future.
Mr. Bickel is currently in Ulaanbaatar and commented, "We expect to announce this major milestone for a Redwood Capital client very shortly. Additional details will be forthcoming. It is difficult to explain how exciting the prospects currently are in the Mongolia market, but as events unfold, S3 shareholders will see that the time and efforts spent on this project have been well worth it."
Mr. Bickel will also meet with the management of the Redwood Medical subsidiary in China and is expected to receive updates regarding the process of securing additional regulatory approvals for the first product it will distribute in the China market. The updates will include new information on clinical and laboratory trials, progress in the selection of hospitals for the clinical trials and the process of securing the necessary equipment and reagents.
While in Hong Kong, Mr. Bickel will attend meetings related to another potential Redwood Capital contract, the first from the Hong Kong market. Mr. Bickel will also be updated on the progress of the Redwood Private Equity Fund periodically during this trip.
To sign up to receive information by email directly from S3 Investment Company when new press releases, investor newsletters, SEC filings or other information is disclosed, please visit http://www.s3investments.com/investors/.
About S3 Investment Company, Inc.
S3 Investment Company, Inc. (http://www.s3investments.com) and its Redwood Group International subsidiary are focused on facilitating the success of several subsidiaries operating in the China market. Redwood Capital, Inc. assists private Chinese companies in accessing the North American capital markets by utilizing a network of investment banking relationships to achieve reverse merger transactions. For more information, please visit http://www.redwoodcapinc.com. Redwood Medical, Inc. assists companies seeking to import and distribute Western medical technologies and products into the China market.
Any statements contained herein related to future events are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on forward-looking statements. S3 Investment Company, Inc. undertakes no obligation to update any such statements to reflect actual events.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: S3 Investment Company, Inc. CONTACT: S3 Investment Company
Investor Relations
951-200-4107
investors@s3investments.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
Comments
Post a Comment